B. Redman

发表

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Chad A. LaGrange, S. Hancock, R. Motzer, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Use of Preoperative PET/CT Staging in Sentinel Lymph Node-Positive Melanoma.

B. Redman, C. Lao, K. Kidwell, 2016, JAMA oncology.

Phase I/II trial of tremelimumab in patients with metastatic melanoma.

B. Redman, J. Sosman, J. Kirkwood, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.

S. Merajver, K. Pienta, V. Sondak, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer.

S. Martino, B. Redman, M. Simon, 1992, Journal of immunotherapy.

Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcoma.

B. Redman, M. Zalupski, L. Baker, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials

B. Redman, D. Hertz, Lauren A Marcath, 2018, BMC Cancer.

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative

V. Sondak, M. Atkins, B. Redman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN clinical practice guidelines in oncology: kidney cancer.

L. Schwartz, R. Figlin, S. Hancock, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.

R. Motzer, M. Harrison, E. Plimack, 2014 .

A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.

T. Braun, J. Geiger, B. Redman, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma.

G. Haas, B. Redman, J. Forman, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma.

M. Atkins, B. Redman, J. Sosman, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adjuvant H igh-Dose B olus I nterleukin-2 f or P atients W ith High-Risk R enal C ell C arcinoma: A C ytokine W orking G roup Randomized T rial

R. Figlin, M. Atkins, B. Redman, 2003 .

Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.

David C. Miller, B. Redman, R. Dunn, 2011, Urology.

The role of immunotherapy in urologic malignancies.

B. Redman, Y. Abubakr, 1996, Cancer treatment and research.

Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC)

R. Motzer, M. Michaelson, B. Redman, 2005 .

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

K. Pienta, B. Redman, M. Strawderman, 1998, Urology.

Advanced renal cell carcinoma

B. Redman, A. Chang, 2000, Current treatment options in oncology.

NCCN clinical practice guidelines in oncology: testicular cancer.

L. Schwartz, R. Figlin, S. Hancock, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology

S. Hancock, R. Motzer, E. Jonasch, 2015 .

Testicular Cancer, Version 2.2015.

S. Hancock, R. Motzer, E. Jonasch, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma.

B. Redman, R. Mohammad, A. Al-Katib, 1995, Leukemia research.

A Phase I Clinical Trial of Spicamycin Derivative KRN5500 (NSC 650426) Using a Phase I Accelerated Titration “2B” Design

B. Redman, A. Wozniak, P. LoRusso, 2003, Investigational New Drugs.

Sunitinib efficacy against advanced renal cell carcinoma.

R. Motzer, M. Michaelson, B. Redman, 2007, The Journal of urology.

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.

B. Redman, D. Smith, W. Du, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate cancer old problems and new approaches

D. Grignon, B. Redman, J. Forman, 1996, Pathology & Oncology Research.

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.

T. Braun, B. Redman, A. Chang, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The times they are a‐changin' (Bob Dylan, 1964)

B. Redman, D. Bradley, 2007, Cancer.

University of Chicago Consortium phase II study of ispinesib (SB-715992) in patients (pts) with advanced renal cell carcinoma (RCC)

B. Redman, R. Dunn, W. Stadler, 2007 .

Testicular cancer. Clinical practice guidelines in oncology.

P. Kantoff, S. Hancock, R. Motzer, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses.

B. Redman, A. Chang, Mu Li, 2008, Cancer research.

Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems.

B. Redman, P. LoRusso, M. Valdivieso, 1990, Cancer research.

Phase Ib Trial Assessing Autologous, Tumor-pulsed Dendritic Cells as a Vaccine Administered With or Without IL-2 in Patients With Metastatic Melanoma

T. Braun, B. Redman, A. Chang, 2008, Journal of immunotherapy.

Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma

B. Redman, A. Alva, J. Rae, 2018, Investigational New Drugs.

Combination P aclitaxel, C arboplatin, a nd G emcitabine I s an A ctive T reatment f or A dvanced U rothelial C ancer

David C. Smith, B. Redman, W. Du, 2001 .

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.

J. Eastham, B. Redman, E. Small, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.

B. Redman, D. Smith, W. Du, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.

K. Pienta, K. Cease, B. Redman, 1997, Urology.

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.

Chad A. LaGrange, Geoffrey E. Wile, S. Hancock, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Spontaneous remission of renal cell carcinoma: a case report and immunological correlates.

B. Redman, T. Chou, Y. Abubakr, 1994, The Journal of urology.

SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial.

R. Figlin, R. Motzer, M. Michaelson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy for metastatic renal cell cancer: effect on the primary tumor.

G. Haas, B. Redman, J. Pontes, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study.

P. Goodman, B. Redman, E. Crawford, 1990, Journal of the National Cancer Institute.

Oral etoposide in the treatment of hormone‐refractory prostate cancer

K. Pienta, B. Redman, M. Hussain, 1994, Cancer.

Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen‐independent prostate carcinoma

David C. Smith, K. Pienta, B. Redman, 2003, Cancer.

SWOG 8825: melphalan GM-CSF: a phase I study.

B. Redman, D. Alberts, E. Poplin, 1992, Gynecologic oncology.

A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.

S. Martino, B. Redman, A. Al-Katib, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of melanoma with a multidisciplinary melanoma clinic model.

B. Redman, C. Bradford, L. Lowe, 2000, Journal of the American Academy of Dermatology.

Concurrent whole brain radiotherapy and bortezomib for brain metastasis

B. Redman, Yue Cao, J. Hayman, 2013, Radiation oncology.

Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions.

B. Redman, M. Riba, P. Trask, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.

V. Sondak, M. Atkins, B. Redman, 2012 .

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin‐2 in metastatic malignant melanoma

S. Martino, B. Redman, R. Gonzalez, 1993, Cancer.

Prospective evaluation of adrenal insufficiency in patients with adrenal metastasis

B. Redman, R. Pazdur, A. Zingas, 1987, Cancer.

Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for malignant melanoma.

Salt lake City, B. Redman, W. Samlowski, 1990, The Western journal of medicine.

Kidney cancer, version 3.2015.

S. Hancock, R. Motzer, E. Jonasch, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Meningeal carcinomatosis in head and neck cancer: Report of six cases and review of the literature

B. Redman, M. al-Sarraf, E. Tapazoglou, 1986, Cancer.

BRAF and NRAS mutations in melanoma and melanocytic nevi

Stephen B Gruber, Bruce Redman, James T. Elder, 2006, Melanoma research.

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.

R. Motzer, E. Plimack, B. Redman, 2016, JAMA oncology.

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

R. Motzer, M. Harrison, E. Plimack, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate Cancer Old Problems and New Approaches

D. Grignon, B. Redman, J. Forman, 1996, Pathology & Oncology Research.

Prostate cancer old problems and new approaches

D. Grignon, B. Redman, J. Forman, 1996, Pathology & Oncology Research.

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.

B. Redman, M. Strawderman, D. Smith, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

Chad A. LaGrange, Geoffrey E. Wile, R. Advani, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Sunitinib in patients with metastatic renal cell carcinoma.

R. Motzer, J. Bacik, M. Michaelson, 2006, JAMA.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

R. Figlin, R. Motzer, M. Michaelson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma.

B. Redman, R. Mohammad, A. Al-Katib, 1995, Anti-cancer drugs.

Placental metastasis of maternal melanoma.

Jennifer L. Schwartz, B. Redman, L. Lowe, 2003, Journal of the American Academy of Dermatology.

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

R. Figlin, M. Atkins, B. Redman, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma

B. Redman, R. Gonzalez, J. Weber, 2014, Cancer medicine.

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

N. Agarwal, E. Lam, T. Olencki, 2014, Journal of immunotherapy.

Weekly 1‐hour infusion of paclitaxel

B. Redman, O. Kucuk, M. Hussain, 2000, Cancer.

Supportive care, pain management, and quality of life in advanced prostate cancer.

B. Redman, P. Esper, 1999, The Urologic clinics of North America.

Psychiatric S ide E ffects o f I nterferon T herapy: P revalence, Proposed M echanisms, a nd F uture D irections

B. Redman, M. Riba, P. Trask, 2000 .

Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2

N. Agarwal, B. Redman, A. Alva, 2016, Cancer Immunology, Immunotherapy.

Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).

D. Grignon, B. Redman, J. Forman, 1996, Pathology oncology research : POR.

Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma.

Jennifer L. Schwartz, V. Sondak, B. Redman, 2004, Journal of the American Academy of Dermatology.

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.

K. Pienta, B. Redman, M. Hussain, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate.

K. Pienta, B. Redman, L. Flaherty, 1996, American journal of clinical oncology.

Phase I trial of spiromustine (NSC 172112) and evaluation of toxicity and schedule in a murine model.

B. Redman, R. Pazdur, L. Baker, 1987, Cancer research.

The impact of BRAF mutation status on clinical outcomes with anti‐PD‐1 monotherapy versus combination ipilimumab/nivolumab in treatment‐naïve advanced stage melanoma

B. Redman, A. Alva, L. Fecher, 2020, Pigment cell & melanoma research.

Selective palliative transcatheter embolization of bony metastases from renal cell carcinoma

B. Redman, A. Forauer, P. Esper, 2007, Acta oncologica.

Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study

B. Redman, J. Sosman, J. Kirkwood, 2007 .

Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports

Mark P. MacEachern, B. Redman, R. Gianchandani, 2019, Clinical Diabetes and Endocrinology.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

C. Porta, R. Motzer, T. Powles, 2019, The Lancet. Oncology.

A phase 2 trial of complete resection for stage IV melanoma

V. Sondak, B. Redman, J. Sosman, 2011, Cancer.

Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon

B. Redman, P. Trask, P. Esper, 2004, Psycho-oncology.

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.

V. Sondak, B. Redman, J. Sosman, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic role of prior cytokine immunotherapy in outcome of treatment with tremelimumab (CP-675,206) in patients with metastatic melanoma

B. Redman, J. Sosman, J. Kirkwood, 2008 .

Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents.

B. Redman, J. Mulé, R. Kunkel, 2001, Cancer research.

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.

S. Hancock, R. Motzer, E. Jonasch, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.

B. Redman, J. Weber, B. Curti, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF‐3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma

B. Redman, H. Zarour, S. O’Day, 2009, Cancer.

Phase II trial of carboplatin and paclitaxel in cisplatin‐pretreated advanced transitional cell carcinoma

B. Redman, E. Small, D. Petrylak, 2005, Cancer.

Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.

B. Redman, A. Nakeff, T. Chou, 1991, Journal of immunotherapy.

A phase I‐II study of dacarbazine in combination with outpatient interleukin‐2 in metastatic malignant melanoma

S. Martino, B. Redman, L. Heilbrun, 1990, Cancer.

Surgical resection for stage IV melanoma: A Southwest Oncology Group trial (S9430).

V. Sondak, B. Redman, J. Sosman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular diagnostics of melanoma fine-needle aspirates: a cytology-histology correlation study.

B. Redman, B. Betz, Kurt D. Bernacki, 2012, American journal of clinical pathology.

Testicular cancer.

P. Kantoff, S. Hancock, R. Motzer, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Improvement Initiative to Develop and Implement a Tool for Detecting Drug-Drug Interactions During Oncology Clinical Trial Enrollment Eligibility Screening

B. Redman, D. Hertz, Faisal Shakeel, 2020, Journal of patient safety.

Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).

R. Motzer, M. Harrison, E. Plimack, 2015 .

Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas

R. Motzer, T. Choueiri, B. Redman, 2018, Clinical Cancer Research.

Prolonged survival after multifocal brain radiation necrosis associated with whole brain radiation for brain metastases: case report

B. Redman, J. Forman, L. Junck, 2008, Journal of Neuro-Oncology.

Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206

B. Redman, J. Sosman, J. Kirkwood, 2007 .

Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer

B. Redman, M. Simon, M. Valdivieso, 1990, Breast Cancer Research and Treatment.

NCCN Kidney Cancer Clinical Practice Guidelines in Oncology

S. Hancock, R. Motzer, E. Jonasch, 2011 .

Kidney Cancer

S. Hancock, R. Motzer, E. Jonasch, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.

B. Redman, J. Mulé, M. Giedlin, 2000, The cancer journal from Scientific American.

Validation of the FACT-BRM with interferon-alpha treated melanoma patients.

B. Redman, L. Wagner, P. Trask, 2005, Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.

Validation of the FACT-BRM with interferon-α treated melanoma patients

B. Redman, L. Wagner, P. Trask, 2005, Quality of Life Research.

Low‐Dose Continuous Infusion 5‐Fluorouracil and Cisplatin: Phase II Evaluation in Advanced Colorectal Carcinoma

B. Redman, R. Pazdur, V. Vaitkevicius, 1989, American journal of clinical oncology.

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team

Aleksandar Sekulic, Jeffrey M Trent, Sally Hunsberger, 2015, Molecular Cancer Therapeutics.

Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma

B. Redman, J. Sosman, J. Kirkwood, 2007 .

Inhibition of prostate cancer growth by estramustine and etoposide

K. Pienta, B. Redman, M. Hussain, 1995, The Journal of urology.

Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer 1

S. Merajver, H. Hussain, B. Redman, 2003 .

Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)

T. Ho, T. Choueiri, N. Agarwal, 2019, Annals of Oncology.

Dorsal Muscle Attenuation May Predict Failure to Respond to Interleukin-2 Therapy in Metastatic Renal Cell Carcinoma.

B. Redman, M. Sabel, A. Alva, 2017, Academic radiology.

Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.

S. Merajver, H. Hussain, B. Redman, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)

R. Motzer, B. Redman, G. V. Kondagunta, 2007 .

A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.

B. Redman, B. Rini, H. Burris, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Kidney cancer. Clinical practice guidelines in oncology.

P. Kantoff, S. Hancock, R. Motzer, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

5‐fluorouracil, etoposide, and cisplatin in the management of metastatic non‐small cell lung cancer

S. Martino, B. Redman, A. Wozniak, 1991, Cancer.

Kidney cancer, version 2.2014.

S. Hancock, R. Motzer, E. Jonasch, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II trial of recombinant interleukin-1β in patients with metastatic renal cell carcinoma

B. Redman, T. Chou, L. Flaherty, 1994 .

Safety and Efficacy of Nivolumab in PatientsWithMetastatic Renal Cell Carcinoma Treated Beyond Progression A Subgroup Analysis of a Randomized Clinical Trial

R. Motzer, E. Plimack, B. Redman, 2016 .

Safety and Efficacy of Nivolumab in PatientsWithMetastatic Renal Cell Carcinoma Treated Beyond Progression

R. Motzer, E. Plimack, B. Redman, 2016 .

Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933

V. Sondak, B. Redman, A. Ribas, 2015, Cancer.

Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC).

R. Motzer, T. Choueiri, B. Redman, 2015 .

Colonic small cell undifferentiated carcinoma: a distinct pathological diagnosis with therapeutic implications.

B. Redman, R. Pazdur, 1987, The American journal of gastroenterology.

Utility of pre-operative PET/CT staging in sentinel lymph node-positive melanoma.

B. Redman, C. Lao, K. Kidwell, 2015 .

Difluorodeoxycytidine (dFdC) — gemcitabine: A phase I study

B. Redman, L. Baker, M. Valdivieso, 1992, Investigational New Drugs.

Phase 2 trial of talabostat in stage IV melanoma

B. Redman, M. Ernstoff, T. Gajewski, 2005 .

The NCCN Kidney Cancer Clinical Practice Guidelines in OncologyTM

L. Schwartz, R. Figlin, S. Hancock, 2009 .

Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials

B. Redman, D. Hertz, Lauren A. Marcath, 2018, BMC Cancer.

Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2).

N. Agarwal, B. Redman, A. Alva, 2015 .

Erratum: Weekly 1-hour infusion of paclitaxel: Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma (Cancer (2000) 89 (431-6))

B. Redman, O. Kucuk, L. Flaherty, 2000 .

Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results of two phase II trials and prognostic factor analysis for survival

R. Motzer, M. Michaelson, B. Redman, 2007 .

Phase I Study of Monoclonal Antibody‐Ricin A Chain Immunoconjugate Xomazyme‐791 in Patients with Metastatic Colon Cancer

J. Bander, B. Redman, P. LoRusso, 1995, American journal of clinical oncology.

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.

Chad A. LaGrange, Geoffrey E. Wile, S. Hancock, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach

R. Motzer, M. Michaelson, B. Redman, 2007 .

Kidney Cancer.

L. Schwartz, R. Figlin, S. Hancock, 2009, Cancer journal.

Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma

R. Motzer, B. Redman, M. Ginsberg, 2010, American journal of clinical oncology.

Preliminary tolerability and anti-tumor activity of intravenous recombinant human Interleukin-21 (IL-21) in patients with metastatic melanoma and metastatic renal cell carcinoma

B. Redman, B. Curti, John A Thompson, 2005 .

501 Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma who were treated beyond progression in a randomized phase 2 dose-ranging trial

R. Motzer, E. Plimack, B. Redman, 2015 .

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Chad A. LaGrange, S. Hancock, R. Motzer, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

CPG 7909, a TLR9 agonist immunomodulator in metastatic melanoma: A randomized phase II trial comparing two doses and in combination with DTIC

B. Redman, H. Zarour, J. Weber, 2005 .

NCCN clinical practice guidelines in oncology: testicular cancer.

L. Schwartz, R. Figlin, S. Hancock, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.

S. Hancock, R. Motzer, E. Jonasch, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

5‐fluorouracil, etoposide, and cisplatin in the management of metastatic non‐small cell lung cancer

S. Martino, B. Redman, A. Wozniak, 1991, Cancer.

Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.

David C. Smith, K. Pienta, K. Cooney, 2007, Clinical genitourinary cancer.

New treatment strategies for hormone refractory prostate cancer.

K. Pienta, B. Redman, 1995, Seminars in urology.

A Systematic Review of Cases of Diabetes Mellitus following Immune Checkpoint Inhibitor Therapy for Cancer

Mark P. MacEachern, B. Redman, R. Gianchandani, 2018, Diabetes.

Dorsal Muscle Attenuation May Predict Failure to Respond to Interleukin-2 Therapy in Metastatic Renal Cell Carcinoma.

B. Redman, M. Sabel, A. Alva, 2017, Academic radiology.